CXCR2 and pancreatic adenocarcinoma: Additionally, combination of SB225002 (CXCR2 inhibitor) with RS504393 (CCR2 inhibitor) overcame the compensatory response of myeloid subset, augmented antitumor immunity and improved chemotherapeutic response of FOLFIRINOX in an orthotopic model of pancreatic adenocarcinoma (182).